Original Research Online Publishing Date: | ||||||||||||
Atherogenesis inhibition by darapladib administration in dyslipidemia model SpragueDawley rats Teuku Heriansyah, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, Lintang Widya Sishartami.
|
How to Cite this Article |
Pubmed Style Teuku Heriansyah, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, Lintang Widya Sishartami. Atherogenesis inhibition by darapladib administration in dyslipidemia model SpragueDawley rats. Natl J Physiol Pharm Pharmacol. 2016; 6(1): 52-58. doi:10.5455/njppp.2015.5.2909201580 Web Style Teuku Heriansyah, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, Lintang Widya Sishartami. Atherogenesis inhibition by darapladib administration in dyslipidemia model SpragueDawley rats. https://www.njppp.com/?mno=203195 [Access: March 14, 2024]. doi:10.5455/njppp.2015.5.2909201580 AMA (American Medical Association) Style Teuku Heriansyah, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, Lintang Widya Sishartami. Atherogenesis inhibition by darapladib administration in dyslipidemia model SpragueDawley rats. Natl J Physiol Pharm Pharmacol. 2016; 6(1): 52-58. doi:10.5455/njppp.2015.5.2909201580 Vancouver/ICMJE Style Teuku Heriansyah, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, Lintang Widya Sishartami. Atherogenesis inhibition by darapladib administration in dyslipidemia model SpragueDawley rats. Natl J Physiol Pharm Pharmacol. (2016), [cited March 14, 2024]; 6(1): 52-58. doi:10.5455/njppp.2015.5.2909201580 Harvard Style Teuku Heriansyah, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, Lintang Widya Sishartami (2016) Atherogenesis inhibition by darapladib administration in dyslipidemia model SpragueDawley rats. Natl J Physiol Pharm Pharmacol, 6 (1), 52-58. doi:10.5455/njppp.2015.5.2909201580 Turabian Style Teuku Heriansyah, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, Lintang Widya Sishartami. 2016. Atherogenesis inhibition by darapladib administration in dyslipidemia model SpragueDawley rats. National Journal of Physiology, Pharmacy and Pharmacology, 6 (1), 52-58. doi:10.5455/njppp.2015.5.2909201580 Chicago Style Teuku Heriansyah, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, Lintang Widya Sishartami. "Atherogenesis inhibition by darapladib administration in dyslipidemia model SpragueDawley rats." National Journal of Physiology, Pharmacy and Pharmacology 6 (2016), 52-58. doi:10.5455/njppp.2015.5.2909201580 MLA (The Modern Language Association) Style Teuku Heriansyah, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, Lintang Widya Sishartami. "Atherogenesis inhibition by darapladib administration in dyslipidemia model SpragueDawley rats." National Journal of Physiology, Pharmacy and Pharmacology 6.1 (2016), 52-58. Print. doi:10.5455/njppp.2015.5.2909201580 APA (American Psychological Association) Style Teuku Heriansyah, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, Lintang Widya Sishartami (2016) Atherogenesis inhibition by darapladib administration in dyslipidemia model SpragueDawley rats. National Journal of Physiology, Pharmacy and Pharmacology, 6 (1), 52-58. doi:10.5455/njppp.2015.5.2909201580 |